Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A confirmatory pharmacokinetic study of OPNT-003

Trial Profile

A confirmatory pharmacokinetic study of OPNT-003

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs Nalmefene (Primary)
  • Indications Opioid abuse
  • Focus Pharmacokinetics; Registrational
  • Sponsors Opiant Pharmaceuticals
  • Most Recent Events

    • 10 Sep 2018 According to an Opiant Pharmaceuticals media release, Opiant intends to initiate this trial in early 2019.
    • 09 Aug 2018 According to an Opiant Pharmaceuticals media release, the company was recently awarded a grant of approximately $7.4 million from the National Institutes of Healths (NIH) which will be used to fund completion of registration study.
    • 29 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top